Gen Sobue

List of Publications by Year
in descending order

139 papers	9,164 citations	44444 50 h-index	51423 90 g-index
148 all docs	148 docs citations	148 times ranked	8495 citing authors

#	Article	IF	Citations
1	Safety and Clinical Benefits of Laryngeal Closure in Patients with Amyotrophic Lateral Sclerosis. Dysphagia, 2023, 38, 211-219.	1.0	4
2	Randomized phase 2 study of perampanel for sporadic amyotrophic lateral sclerosis. Journal of Neurology, 2022, 269, 885-896.	1.8	15
3	Fiberâ€specific white matter analysis reflects upper motor neuron impairment in amyotrophic lateral sclerosis. European Journal of Neurology, 2022, 29, 432-440.	1.7	5
4	ANCA-Associated Vasculitic Neuropathies: A Review. Neurology and Therapy, 2022, 11, 21-38.	1.4	17
5	Analysis of relapse by inflammatory Raschâ€built overall disability scale status in the <scp>PATH</scp> study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Journal of the Peripheral Nervous System, 2022, 27, 159-165.	1.4	3
6	Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration. Brain, 2022, 145, 2769-2784.	3.7	15
7	Mutation screening of the DNAJC7 gene in Japanese patients with sporadic amyotrophic lateral sclerosis. Neurobiology of Aging, 2022, 113, 131-136.	1.5	6
8	Functional connector hubs in the cerebellum. NeuroImage, 2022, 257, 119263.	2.1	8
9	Actin-binding protein filamin-A drives tau aggregation and contributes to progressive supranuclear palsy pathology. Science Advances, 2022, 8, .	4.7	15
10	Genetic and functional analysis of KIF5A variants in Japanese patients with sporadic amyotrophic lateral sclerosis. Neurobiology of Aging, 2021, 97, 147.e11-147.e17.	1.5	11
11	Two distinct mechanisms of neuropathy in immunoglobulin light chain (AL) amyloidosis. Journal of the Neurological Sciences, 2021, 421, 117305.	0.3	6
12	Clinicoradiological features in amyotrophic lateral sclerosis patients with olfactory dysfunction. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 260-266.	1.1	4
13	DNA damage in embryonic neural stem cell determines FTLDsâ€™ fate via early-stage neuronal necrosis. Life Science Alliance, 2021, 4, e202101022.	1.3	5
14	Case of Neuronal Intranuclear Inclusion Disease With Dynamic Perfusion Changes Lacking Typical Signs on Diffusion-Weighted Imaging. Neurology: Genetics, 2021, 7, e601.	0.9	9
15	Nerve biopsy in acquired neuropathies. Journal of the Peripheral Nervous System, 2021, 26 Suppl 2, S21-S41.	1.4	2
16	Bridging large-scale cortical networks: Integrative and function-specific hubs in the thalamus. IScience, 2021, 24, 103106.	1.9	13
17	FXTAS is difficult to differentiate from neuronal intranuclear inclusion disease through skin biopsy: a case report. BMC Neurology, 2021, 21, 396.	0.8	21
18	Effects of Head Motion on the Evaluation of Age-related Brain Network Changes Using Resting State Functional MRI. Magnetic Resonance in Medical Sciences, 2021, 20, 338-346.	1.1	5

#	Article	IF	Citations
19	Resting State Networks Related to the Maintenance of Good Cognitive Performance During Healthy Aging. Frontiers in Human Neuroscience, 2021, 15, 753836.	1.0	1
20	Instability of speech in Parkinson disease patients with subthalamic nucleus deep brain stimulation. Parkinsonism and Related Disorders, 2021, 93, 8-11.	1.1	3
21	Characteristics of Neural Network Changes in Normal Aging and Early Dementia. Frontiers in Aging Neuroscience, 2021, 13, 747359.	1.7	20
22	Association Between IL-5 Levels and the Clinicopathologic Features of Eosinophilic Granulomatosis With Polyangiitis. Neurology, 2021, 96, 226-229.	1.5	5
23	Patientâ€reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study. European Journal of Neurology, 2020, 27, 196-203.	1.7	11
24	A multi-ethnic meta-analysis identifies novel genes, including ACSL5, associated with amyotrophic lateral sclerosis. Communications Biology, 2020, 3, 526.	2.0	49
25	Serum IgG anti-GD1a antibody and mEGOS predict outcome in Guillain-BarrÃ© syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1339-1342.	0.9	13
26	Identifying the brain's connector hubs at the voxel level using functional connectivity overlap ratio. NeuroImage, 2020, 222, 117241.	2.1	19
27	Cerebello-basal ganglia connectivity fingerprints related to motor/cognitive performance in Parkinson's disease. Parkinsonism and Related Disorders, 2020, 80, 21-27.	1.1	15
28	The neural network basis of altered decisionâ€making in patients with amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology, 2020, 7, 2115-2126.	1.7	10
29	Individual changes in visual performance in non-demented Parkinson's disease patients: a 1-year follow-up study. Journal of Neural Transmission, 2020, 127, 1387-1397.	1.4	3
30	Aging Impacts the Overall Connectivity Strength of Regions Critical for Information Transfer Among Brain Networks. Frontiers in Aging Neuroscience, 2020, 12, 592469.	1.7	16
31	Reply to â€œ<scp>GGC</scp> Repeat Expansion of <scp>NOTCH2NLC</scp> is Rare in European Leukoencephalopathyâ€. Annals of Neurology, 2020, 88, 642-643.	2.8	2
32	Unveiling synapse pathology in spinal bulbar muscular atrophy by genome-wide transcriptome analysis of purified motor neurons derived from disease specific iPSCs. Molecular Brain, 2020, 13, 18.	1.3	19
33	YAP-dependent necrosis occurs in early stages of Alzheimerâ€™s disease and regulates mouse model pathology. Nature Communications, 2020, 11, 507.	5.8	62
34	Differential clinicopathologic features of EGPA-associated neuropathy with and without ANCA. Neurology, 2020, 94, e1726-e1737.	1.5	58
35	Ultrastructural mechanisms of macrophage-induced demyelination in Guillain-BarrÃ© syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 650-659.	0.9	31
36	Changes in white matter fiber density and morphology across the adult lifespan: A crossâ€sectional fixelâ€based analysis. Human Brain Mapping, 2020, 41, 3198-3211.	1.9	34

#	Article	IF	Citations
37	Prognosis of amyotrophic lateral sclerosis patients undergoing tracheostomy invasive ventilation therapy in Japan. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 285-290.	0.9	30
38	Reorganization of brain networks and its association with general cognitive performance over the adult lifespan. Scientific Reports, 2019, 9, 11352.	1.6	66
39	GGC Repeat Expansion of NOTCH2NLC in Adult Patients with Leukoencephalopathy. Annals of Neurology, 2019, 86, 962-968.	2.8	98
40	A behavior-based drug screening system using a Caenorhabditis elegans model of motor neuron disease. Scientific Reports, 2019, 9, 10104.	1.6	25
41	Long-read sequencing identifies GGC repeat expansions in NOTCH2NLC associated with neuronal intranuclear inclusion disease. Nature Genetics, 2019, 51, 1215-1221.	9.4	328
42	Semantic deficits in ALS related to right lingual/fusiform gyrus network involvement. EBioMedicine, 2019, 47, 506-517.	2.7	22
43	Src inhibition attenuates polyglutamine-mediated neuromuscular degeneration in spinal and bulbar muscular atrophy. Nature Communications, 2019, 10, 4262.	5.8	13
44	Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the preâ€randomization phase of the Polyneuropathy And Treatment with Hizentra study. Journal of the Peripheral Nervous System, 2019, 24, 72-79.	1.4	13
45	Clinicopathological characteristics of subtypes of chronic inflammatory demyelinating polyradiculoneuropathy. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 988-996.	0.9	56
46	Functional evaluation of PDGFB-variants in idiopathic basal ganglia calcification, using patient-derived iPS cells. Scientific Reports, 2019, 9, 5698.	1.6	8
47	Increase of arginine dimethylation correlates with the progression and prognosis of ALS. Neurology, 2019, 92, e1868-e1877.	1.5	17
48	DNA methylation inhibitor attenuates polyglutamineâ€induced neurodegeneration by regulating Hes5. EMBO Molecular Medicine, 2019, 11, .	3.3	16
49	TDP-43 regulates early-phase insulin secretion via CaV1.2-mediated exocytosis in islets. Journal of Clinical Investigation, 2019, 129, 3578-3593.	3.9	32
50	Safety and efficacy of eculizumab in Guillain-BarrÃ© syndrome: a multicentre, double-blind, randomised phase 2 trial. Lancet Neurology, The, 2018, 17, 519-529.	4.9	111
51	Distinct manifestation of cognitive deficits associate with different resting-state network disruptions in non-demented patients with Parkinsonâ€™s disease. Journal of Neurology, 2018, 265, 688-700.	1.8	34
52	Biomarker-based analysis of preclinical progression in spinal and bulbar muscular atrophy. Neurology, 2018, 90, e1501-e1509.	1.5	30
53	An unbiased data-driven age-related structural brain parcellation for the identification of intrinsic brain volume changes over the adult lifespan. NeuroImage, 2018, 169, 134-144.	2.1	44
54	Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2018, 17, 35-46.	4.9	193

#	Article	IF	Citations
55	Ultrastructural mechanisms of macrophage-induced demyelination in CIDP. Neurology, 2018, 91, 1051-1060.	1.5	64
56	Age-related impairment in Addenbrookeâ€™s cognitive examination revised scores in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 578-584.	1.1	3
57	Restoration of a Conduction Block after the Long-term Treatment of CIDP with Anti-neurofascin 155 Antibodies: Follow-up of a Case over 23 Years. Internal Medicine, 2018, 57, 2061-2066.	0.3	11
58	Severe hyposmia and aberrant functional connectivity in cognitively normal Parkinsonâ€™s disease. PLoS ONE, 2018, 13, e0190072.	1.1	39
59	Treatment with Creatine Monohydrate in Spinal and Bulbar Muscular Atrophy: Protocol for a Randomized, Double-Blind, Placebo-Controlled Trial. JMIR Research Protocols, 2018, 7, e69.	0.5	9
60	4. Pathogenesis and Treatment of Dementia. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 1804-1809.	0.0	0
61	Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin-155 and anti-contactin-1 antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 465-473.	0.9	151
62	Case of adult-onset neuronal intranuclear hyaline inclusion disease with negative electroretinogram. Documenta Ophthalmologica, 2017, 134, 221-226.	1.0	17
63	Structural MRI correlates of amyotrophic lateral sclerosis progression. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 901-907.	0.9	33
64	3â€²UTR Length-Dependent Control of SynGAP Isoform Î±2 mRNA by FUS and ELAV-like Proteins Promotes Dendritic Spine Maturation and Cognitive Function. Cell Reports, 2017, 20, 3071-3084.	2.9	64
65	Pathologic Involvement of Glutamatergic Striatal Inputs From the Cortices in TAR DNA-Binding Protein 43â€‰kDa-Related Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Journal of Neuropathology and Experimental Neurology, 2017, 76, 759-768.	0.9	12
66	Markers for Guillainâ€“BarrÃ© syndrome with poor prognosis: a multiâ€center study. Journal of the Peripheral Nervous System, 2017, 22, 433-439.	1.4	46
67	Long-term treatment with leuprorelin for spinal and bulbar muscular atrophy: natural history-controlled study. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 1026-1032.	0.9	40
68	Distinct pathogenesis in nonsystemic vasculitic neuropathy and microscopic polyangiitis. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e407.	3.1	18
69	Reply: Neuronal intranuclear (hyaline) inclusion disease and fragile X-associated tremor/ataxia syndrome: a morphological and molecular dilemma. Brain, 2017, 140, e52-e52.	3.7	12
70	Memory Loss and Frontal Cognitive Dysfunction in a Patient with Adult-onset Neuronal Intranuclear Inclusion Disease. Internal Medicine, 2016, 55, 2281-2284.	0.3	28
71	Impaired muscle uptake of creatine in spinal and bulbar muscular atrophy. Annals of Clinical and Translational Neurology, 2016, 3, 537-546.	1.7	38
72	Age of onset differentially influences the progression of regional dysfunction in sporadic amyotrophic lateral sclerosis. Journal of Neurology, 2016, 263, 1129-1136.	1.8	25

#	Article	IF	Citations
73	Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial. Trials, 2016, 17, 345.	0.7	21
74	Involvement of the caudate nucleus head and its networks in sporadic amyotrophic lateral sclerosis-frontotemporal dementia continuum. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 571-579.	1.1	23
75	Clinicopathological features of adult-onset neuronal intranuclear inclusion disease. Brain, 2016, 139, 3170-3186.	3.7	268
76	HMGB1, a pathogenic molecule that induces neurite degeneration via TLR4-MARCKS, is a potential therapeutic target for Alzheimerâ€™s disease. Scientific Reports, 2016, 6, 31895.	1.6	111
77	Schwann cell and endothelial cell damage in transthyretin familial amyloid polyneuropathy. Neurology, 2016, 87, 2220-2229.	1.5	85
78	Marked Involvement of the Striatal Efferent System in TAR DNA-Binding Protein 43â€‰kDa-Related Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Journal of Neuropathology and Experimental Neurology, 2016, 75, 801-811.	0.9	17
79	Next-generation sequencing of 28 ALS-related genes in a Japanese ALS cohort. Neurobiology of Aging, 2016, 39, 219.e1-219.e8.	1.5	49
80	A rapid functional decline type of amyotrophic lateral sclerosis is linked to low expression ofTTN. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 851-858.	0.9	33
81	Decreased Peak Expiratory Flow Associated with Muscle Fiber-Type Switching in Spinal and Bulbar Muscular Atrophy. PLoS ONE, 2016, 11, e0168846.	1.1	22
82	Uncompacted Myelin Lamellae and Nodal Ion Channel Disruption in POEMS Syndrome. Journal of Neuropathology and Experimental Neurology, 2015, 74, 1127-1136.	0.9	12
83	Clinicopathologic features of folate-deficiency neuropathy. Neurology, 2015, 84, 1026-1033.	1.5	60
84	Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 230-236.	1.1	76
85	A functional scale for spinal and bulbar muscular atrophy: Cross-sectional and longitudinal study. Neuromuscular Disorders, 2015, 25, 554-562.	0.3	50
86	Silencing neuronal mutant androgen receptor in a mouse model of spinal and bulbar muscular atrophy. Human Molecular Genetics, 2015, 24, 5985-5994.	1.4	48
87	FUS regulates AMPA receptor function and FTLD/ALS-associated behaviour via GluA1 mRNA stabilization. Nature Communications, 2015, 6, 7098.	5.8	129
88	Pioglitazone suppresses neuronal and muscular degeneration caused by polyglutamine-expanded androgen receptors. Human Molecular Genetics, 2015, 24, 314-329.	1.4	32
89	Tongue pressure as a novel biomarker of spinal and bulbar muscular atrophy. Neurology, 2014, 82, 255-262.	1.5	57
90	Neuronal intranuclear inclusion disease cases with leukoencephalopathy diagnosed via skin biopsy. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 354-356.	0.9	106

#	Article	IF	Citations
91	Lower Motor Neuron Involvement in TAR DNA-Binding Protein of 43 kDaâ€“Related Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. JAMA Neurology, 2014, 71, 172.	4.5	33
92	Neuronal Intranuclear Inclusion Disease Presenting with Resting Tremor. Case Reports in Neurology, 2014, 6, 176-180.	0.3	19
93	Heat shock factor-1 influences pathological lesion distribution of polyglutamine-induced neurodegeneration. Nature Communications, 2013, 4, 1405.	5.8	45
94	Clinicopathological features of neuropathy associated with lymphoma. Brain, 2013, 136, 2563-2578.	3.7	146
95	Loss of TDP-43 causes age-dependent progressive motor neuron degeneration. Brain, 2013, 136, 1371-1382.	3.7	168
96	dnc-1/dynactin 1 Knockdown Disrupts Transport of Autophagosomes and Induces Motor Neuron Degeneration. PLoS ONE, 2013, 8, e54511.	1.1	85
97	Longitudinal changes of outcome measures in spinal and bulbar muscular atrophy. Brain, 2012, 135, 2838-2848.	3.7	57
98	Naratriptan mitigates CGRP1-associated motor neuron degeneration caused by an expanded polyglutamine repeat tract. Nature Medicine, 2012, 18, 1531-1538.	15.2	39
99	Analysis of C9orf72 repeat expansion in 563 Japanese patients with amyotrophic lateral sclerosis. Neurobiology of Aging, 2012, 33, 2527.e11-2527.e16.	1.5	98
100	Crossâ€sectional and longitudinal analysis of an oxidative stress biomarker for spinal and bulbar muscular atrophy. Muscle and Nerve, 2012, 46, 692-697.	1.0	11
101	Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2. Nature Medicine, 2012, 18, 1136-1141.	15.2	139
102	Pathogenesis and therapy of spinal and bulbar muscular atrophy (SBMA). Progress in Neurobiology, 2012, 99, 246-256.	2.8	99
103	Insulinlike Growth Factor (IGF)-1 Administration Ameliorates Disease Manifestations in a Mouse Model of Spinal and Bulbar Muscular Atrophy. Molecular Medicine, 2012, 18, 1261-1268.	1.9	56
104	Molecular Pathophysiology and Disease-Modifying Therapies for Spinal and Bulbar Muscular Atrophy. Archives of Neurology, 2012, 69, 436.	4.9	22
105	Difference in chronological changes of outcome measures between untreated and placebo-treated patients of spinal and bulbar muscular atrophy. Journal of Neurology, 2012, 259, 712-719.	1.8	19
106	Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy: a practical analysis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 53-62.	1.4	98
107	Skin biopsy is useful for the antemortem diagnosis of neuronal intranuclear inclusion disease. Neurology, 2011, 76, 1372-1376.	1.5	162
108	Morphological Progression of Myelin Abnormalities in IgM-Monoclonal Gammopathy of Undetermined Significance Anti-Myelin-Associated Glycoprotein Neuropathy. Journal of Neuropathology and Experimental Neurology, 2010, 69, 1143-1157.	0.9	48

#	Article	IF	Citations
109	Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2010, 9, 875-884.	4.9	170
110	Peripheral Nerve Society Guideline* on the classification, diagnosis, investigation, and immunosuppressive therapy of nonâ€systemic vasculitic neuropathy: executive summary. Journal of the Peripheral Nervous System, 2010, 15, 176-184.	1.4	276
111	Microarray Analysis of Gene Expression by Skeletal Muscle of Three Mouse Models of Kennedy Disease/Spinal Bulbar Muscular Atrophy. PLoS ONE, 2010, 5, e12922.	1.1	49
112	Disrupted Transforming Growth Factor-Î² Signaling in Spinal and Bulbar Muscular Atrophy. Journal of Neuroscience, 2010, 30, 5702-5712.	1.7	76
113	TDP-43 Depletion Induces Neuronal Cell Damage through Dysregulation of Rho Family GTPases. Journal of Biological Chemistry, 2009, 284, 22059-22066.	1.6	84
114	Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Annals of Neurology, 2009, 65, 140-150.	2.8	147
115	Age at onset influences on wide-ranged clinical features of sporadic amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2009, 276, 163-169.	0.3	98
116	Spatiotemporal Recapitulation of Central Nervous System Development by Murine Embryonic Stem Cell-Derived Neural Stem/Progenitor Cells. Stem Cells, 2008, 26, 3086-3098.	1.4	162
117	CHIP Overexpression Reduces Mutant Androgen Receptor Protein and Ameliorates Phenotypes of the Spinal and Bulbar Muscular Atrophy Transgenic Mouse Model. Journal of Neuroscience, 2007, 27, 5115-5126.	1.7	136
118	Gene Expressions Specifically Detected in Motor Neurons (Dynactin 1, Early Growth Response 3,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 3 Markers in Sporadic Amyotrophic Lateral Sclerosis. Journal of Neuropathology and Experimental Neurology, 2007, 66, 617-627.	0.9	36
119	Nonmyelinating Schwann Cell Involvement With Well-Preserved Unmyelinated Axons in Charcot-Marie-Tooth Disease Type 1A. Journal of Neuropathology and Experimental Neurology, 2007, 66, 1027-1036.	0.9	32
120	Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients. Brain, 2006, 129, 1446-1455.	3.7	245
121	Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients. Brain, 2005, 128, 659-670.	3.7	182
122	17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nature Medicine, 2005, 11, 1088-1095.	15.2	363
123	Gene expression profile of spinal motor neurons in sporadic amyotrophic lateral sclerosis. Annals of Neurology, 2005, 57, 236-251.	2.8	231
124	Neuronal intranuclear hyaline inclusion disease showing motor-sensory and autonomic neuropathy. Neurology, 2005, 65, 1538-1543.	1.5	60
125	Age associated axonal features in HNPP with 17p11.2 deletion in Japan. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 1109-1114.	0.9	62
126	Clinical and electrophysiologic correlates of IVIg responsiveness in CIDP. Neurology, 2005, 64, 1471-1475.	1.5	76

#	Article	IF	Citations
127	Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Human Molecular Genetics, 2004, 13, 1183-1192.	1.4	234
128	Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nature Medicine, 2003, 9, 768-773.	15.2	286
129	Chronic inflammatory demyelinating polyneuropathy presenting with features of GBS. Neurology, 2002, 58, 979-982.	1.5	61
130	Testosterone Reduction Prevents Phenotypic Expression in a Transgenic Mouse Model of Spinal and Bulbar Muscular Atrophy. Neuron, 2002, 35, 843-854.	3.8	452
131	Painful alcoholic polyneuropathy with predominant small-fiber loss and normal thiamine status. Neurology, 2001, 56, 1727-1732.	1.5	136
132	Axonal pathology in Japanese Guillainâ€Bard syndrome. Neurology, 1997, 48, 1694-1700.	1.5	45
133	MRI Demonstrates Dorsal Column Involvement of the Spinal Cord in Sjogren's syndrome-associated Neuropathy. Neurology, 1995, 45, 592-593.	1.5	32
134	Serial MRI of olivary hypertrophy: long-term follow-up of a patient with the ?top of the basilar? syndrome. Neuroradiology, 1995, 37, 427-428.	1.1	1
135	Extensive demyelinating changes in the peripheral nerves of Crow-Fukase syndrome: a pathological study of one autopsied case. Acta Neuropathologica, 1992, 84, 171-177.	3.9	35
136	Phosphorylated high molecular weight neurofilament protein in lower motor neurons in amyotrophic lateral sclerosis and other neurodegenerative diseases involving ventral horn cells. Acta Neuropathologica, 1990, 79, 402-408.	3.9	116
137	X-LINKED RECESSIVE BULBOSPINAL NEURONOPATHY. Brain, 1989, 112, 209-232.	3.7	396
138	Nerve growth factor receptor immunoreactivity in the neuronal perikarya of human sensory and sympathetic nerve ganglia. Neurology, 1989, 39, 937-937.	1.5	24
139	Chronic progressive sensory ataxic neuropathy with polyclonal gammopathy and disseminated focal perivascular cellular infiltrations. Neurology, 1988, 38, 463-463.	1.5	26